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Numerous influenza pandemics in the last century resulted 
in the death of millions of people worldwide. With the 
current and future threats of influenza pandemics 
development of new antiviral compounds remains a great 
demand. However, currently only a limited number of 
drugs are available for the treatment and prophylaxis of 
influenza. A neuraminidase (NA) inhibitor, oseltamivir 
phosphate, is the most commonly used antiviral drug. 
However, a number of reports suggest the emergence of 
oseltamivir phosphate resistance in new seasonal influenza 
viruses and highly pathogenic avian influenza (H5N1) (for 
example, de Jong et al, 2005). 
 
(–)-Epigallocatechin-3-O-gallate (EGCG: 1), a major 
component of green tea plant (Camellia sinensis), has been 
recognized to possess antiviral properties. Reports on the 
anti-influenza activity of 1 found that it inhibited virus 
adsorption (Nakayama et al, 1993), as well as acidification 
of endosomes and lysosomes (Imanishi et al, 2002). Such 
virus inhibition activity is different from other current NA 
or proton pump inhibitors, suggesting that 1 can be 
developed into a new class of antiviral compounds that are 
effective against current drug resistant influenza strains. 
However, 1 has not been used as an antiviral compound 
because of its poor lipid membrane permeability and low 
chemical stability. It was previously reported that the 
introduction of long alkyl chain groups to 1 improved its 
lipid membrane permeability (Tanaka et al, 1998), while 
protection of its hydroxyl groups with acyl groups 
increased its chemical stability under physiological 
conditions (Lam et al, 2004). Recently, we reported a 
method to synthesize EGCG-fatty acid monoesters using 
lipase-catalyzed transesterification and demonstrated that 
EGCG-fatty acids monoesters possessed improved 
influenza virus inhibitory effect against influenza 
A/PR8/34/(H1N1) in an alkyl length dependent manner 
(Mori et al, 2008). Here, we investigated the spectrum of 
influenza virus inhibition activity of EGCG (1) and 
EGCG-C-16 (2). As shown in Figure 1a, 2 is a mixture of 
four regio-isomers and the ratio of each regio-isomer 
2a:2b:2c:2d is 38:35:7:20, respectively. Because the B-
ring-modified esters (2a and 2b) and D-ring-modified 
esters (2c and 2d) showed exactly the same antiviral 
activities (data not shown), we used the mixture of four 
regio-isomers (2a-d) in the following assays. 
 
A series of human influenza viruses, an experimental 
strain (A/Puerto Rico/8/34/(H1N1)), vaccine strains 
(A/Beijing/262/95/(H1N1), A/Panama/2007/99/(H3N2), 
and B/Yamanashi/166/98/), drug-resistant strains 
(Yokohama/77/2008/(H1N1) OPR: oseltamivir phosphate-
resistant (OPR), Yokohama/63/2007/(H1N1) AR: 
amantadine-resistant (AR), A/Yokohama/91/2008/(H1N1) 
OPR/AR: (OPR/AR) and avian pathogenic influenza 
(A/Duck/Hong Kong/342/78/(H5N2)), were directly 
incubated with 1 or 2 for 30min prior to inoculation into 
MDCK cells. The cells were inoculated with virus, with or 
without the compounds, for 1hr, and the direct virus 
inhibitory effects were assessed by a plaque formation 
assay at 54hr post-incubation. The plaque inhibition 
activity was calculated relative to no compound. The 
cytotoxicity of compounds on MDCK cells were evaluated 
by the MTT cell proliferation assay. Briefly, the cells were 
incubated with 1 or 2 for 24hr for the MTT assay. The 
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Figure 1. A. Chemical structure of EGCG (1) and EGCG-C16 (2). 2 is a mixture of four regio-isomers (2a-d). 2a: R
2
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CO(CH)14CH3. B. Avian influenza virus inhibition activity of 1 and 2 in chicken embryonated eggs. Influenza A/Duck/Hong 
Kong/342/78 (H5N2) was pretreated with or without 1.0μM compounds and then inoculated (50 pfu/egg) into the allantoic fluid of 
embryonated eggs for 7 days at 37 °C. Open circle, no compound; Closed circle, 1.0μM EGCG-16 (2); Open square, 1.0μM EGCG 
(1); Closed square, 1.0μM Zanamivir; Open lozenge, 1.0μM Oseltamivir phosphate. 
 
 
 results of the plaque inhibition assay and MTT assay are 
expressed as mean ± standard error of three independent 
experiments. 
 
We also investigated the virus inhibition activity of 1 and 
2 on avian influenza A/Duck/Hong Kong/342/78 (H5N2) 
virus in ovo using 11-day-old chicken embryonated eggs 
(n=12) inoculated with compound-treated or untreated 
viruses. 
 
As shown in Table 1, both 1 and 2 showed broad virus 
inhibitory effects on MDCK cells. The EC50 values of 2 on 
these viruses were between 10 to 61nM, which were 
approximately 7.1 to 44-fold lower than those of 1. The 
CC50 value of 2 was 82μM, which was only 3.1-fold lower 
than that of 1 (255 μM). Thus, the SI value of 2 was 
improved 2.2 to 14-fold compared to 1.  
With respect to the avian influenza virus inhibition assay 
in ovo, virus treated with 1, zanamivir, or oseltamivir 
phosphate showed a moderate viral inhibitory effect 
(Figure 1b). However, 2 almost completely inhibited the 
infection (Figure. 1b), and the efficacy was retained even 
at 0.1μM (data not shown). 
In summary, 2 inhibited human and avian influenza A and 
B viruses, including drug-resistant viruses. 2 was found to 
be more effective than neuraminidase inhibitors, and 
strongly inhibited the infection of avian influenza (H5N2) 
virus in chicken embryonated eggs. This unique viral 
inhibitory action has the potential to be utilized to 
effectively control a broad spectrum of influenza viruses. 
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Table 1. Direct virus inhibitory effect of 1 and 2 based on the plaque formation assay 
 
  Direct virus inhibitory effect
a   SI
b 
Virus EC50
c (μM)   CC50
d / EC50 
  1 2    1  2 
A/Puerto Rico8/34 (H1N1)  0.391±0.056  0.020±0.007    653  4062 
A/Beijing/262/95 (H1N1)  0.436±0.081  0.061±0.008    585  1331 
A/Yokohama/77/2008 (H1N1) OPR
e 0.400±0.042  0.017±0.008    638  4779 
A/Yokohama/63/2008 (H1N1) AR
f 0.540±0.042  0.027±0.008    472  3009 
A/Yokohama/91/2008 (H1N1) OPR/AR  0.597±0.015  0.036±0.012    427  2256 
A/Panama/2007/99 (H3N2)  0.173±0.006  0.010±0.004    1476  8125 
A/Duck/Hong Kong/342/78 (H5N2)  0.657±0.022  0.015±0.006    388  5416 
B/Yamanashi/166/98 0.490±0.053  0.024±0.008    521  3385 
 
aDirect virus inhibitory effect: Virus treated with 1 or 2 for 30min at 37 °C prior to the inoculation and then inoculated for 2 days at 
37°C. MDCK cells, MIO: 2.5 x 10
-4 pfu/cell. 
bSI (selectivity index) is the ratio of CC50 and EG50.  
cEC50 represents the concentration of compound required to reduce plaque number by 50% relative to the control well without test 
compound. 
dCC50 represents the concentration of compound required to reduce cell viability by 50% relative to the control well without test 
compound. The CC50 for 1 and 2 were 255.7 ± 6.0 and 81.2 ± 12.5μM, respectively.  
eOPR: oseltamivir phosphate-resistant virus 
fAR: amantadine-resistant virus 
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